Aclaris therapeutics completes enrollment in phase 2b study of oral zunsemetinib (ati-450) for moderate to severe rheumatoid arthritis (ati-450-ra-202)

- topline data anticipated in q4 2023 wayne, pa., june 13, 2023 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the completion of enrollment into ati-450-ra-202, its phase 2b trial of oral zunsemetinib in patients with moderate to severe rheumatoid arthritis (ra).
ACRS Ratings Summary
ACRS Quant Ranking